To the Editor The recently published Original Investigation by Theelen and colleagues regarding the PEMBRO-RT trial¹ has brought promising and encouraging results for the efficacy and safety of stereotactic body radiotherapy (SBRT) followed by treatment with pembrolizumab compared with treatment with pembrolizumab alone in patients with advanced non–small cell lung cancer (NSCLC) that progressed after at least 1 regimen of chemotherapy, though the primary end point was not reached. However, in addition to the perspectives and limitations mentioned by the authors, several other issues deserve attention.

中文翻译：

---

超越 PEMBRO-RT 试验的结果

致编辑Theelen 及其同事最近发表的关于 PEMBRO-RT 试验的原始调查¹为立体定向全身放射治疗 (SBRT) 的疗效和安全性带来了有希望和令人鼓舞的结果，随后使用派姆单抗治疗与单独使用派姆单抗治疗患者相比晚期非小细胞肺癌 (NSCLC) 在至少 1 种化疗方案后进展，但未达到主要终点。然而，除了作者提到的观点和局限性之外，还有其他几个问题值得关注。